These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9890156)

  • 41. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
    McKillop D; Wild MJ; Butters CJ; Simcock C
    Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
    Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
    J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
    Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
    Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
    Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of brucine combined with glycyrrhetinic acid or liquiritin on rat hepatic cytochrome P450 activities in vivo.
    Xing PP; Wu WH; Du P; Han FM; Chen Y
    Yao Xue Xue Bao; 2011 May; 46(5):573-80. PubMed ID: 21800547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
    Yeung JH; Or PM
    Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme.
    Miyata N; Taniguchi K; Seki T; Ishimoto T; Sato-Watanabe M; Yasuda Y; Doi M; Kametani S; Tomishima Y; Ueki T; Sato M; Kameo K
    Br J Pharmacol; 2001 Jun; 133(3):325-9. PubMed ID: 11375247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism.
    Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
    Biopharm Drug Dispos; 2002 Jul; 23(5):183-90. PubMed ID: 12116049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.
    Brøsen K
    Ther Drug Monit; 1996 Aug; 18(4):393-6. PubMed ID: 8857557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetics and pharmacogenomics.
    Leeder JS
    Pediatr Clin North Am; 2001 Jun; 48(3):765-81. PubMed ID: 11411304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.
    Anderson GD
    J Gend Specif Med; 2002; 5(1):25-33. PubMed ID: 11859684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
    Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA
    Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytochrome P450 isozymes and antiepileptic drug interactions.
    Levy RH
    Epilepsia; 1995; 36 Suppl 5():S8-13. PubMed ID: 8806399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation.
    McSorley LC; Daly AK
    Biochem Pharmacol; 2000 Aug; 60(4):517-26. PubMed ID: 10874126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative evaluation of bromodichloromethane metabolism by recombinant rat and human cytochrome P450s.
    Allis JW; Zhao G
    Chem Biol Interact; 2002 May; 140(2):137-53. PubMed ID: 12076521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance.
    Vormfelde SV
    Arch Intern Med; 2001 Apr; 161(7):1012-3. PubMed ID: 11295969
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.